Overcoming asset transfer challenges during a merger and acquisition (M&A)
In this video, Parexel’s Paul Bridges speaks with Phil Smith about how pharma and biotech can overcome common operational challenges and key considerations for a more successful asset transfer.
Related Insights
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Related Insights
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025